Effect of taurine on advanced glycation end products-induced hypertrophy in renal tubular epithelial cells

Toxicology and Applied Pharmacology

Volumn 233, Issue 2, 2008, Pages 220-226

  Huang, Jau Shyang ^a   Chuang, Lea Yea ^b   Guh, Jinn Yuh ^b   Yang, Yu Lin ^a   Hsu, Min Shyang ^a  

^a CHUNG HWA UNIVERSITY OF MEDICAL TECHNOLOGY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Advanced glycation end products; Hypertrophy; Renal tubular epithelial cells; Taurine

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 3 (3,5 DIBROMO 4 HYDROXYBENZYLIDENE) 1,3 DIHYDRO 5 IODO 2 INDOLONE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; BOVINE SERUM ALBUMIN; CASPASE 3; COLLAGEN TYPE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYTOCHROME C; FIBRONECTIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BCL 2; RAF PROTEIN; TAURINE;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE PROGRESSION; CELL DEATH; CELL PROLIFERATION; CELL SIZE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENZYME ACTIVATION; ENZYME INACTIVATION; KIDNEY FIBROSIS; KIDNEY HYPERTROPHY; KIDNEY TUBULE EPITHELIUM; MITOGENESIS; NONHUMAN; PROTEIN EXPRESSION;

ANIMALS; ANTIOXIDANTS; CELL CYCLE; CELL PROLIFERATION; COLLAGEN TYPE IV; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DIABETIC NEPHROPATHIES; EPITHELIAL CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBRONECTINS; FLAVONOIDS; GLYCOSYLATION END PRODUCTS, ADVANCED; HYPERTROPHY; INDOLES; KIDNEY TUBULES; LLC-PK1 CELLS; PHENOLS; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTORS, IMMUNOLOGIC; SWINE; TAURINE;

EID: 56049110188     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2008.09.002     Document Type: Article

References (33)

1. Abebe W. Effects of taurine on the reactivity of aortas from diabetic rats. Life Sci. 82 (2008) 279-289
2. Biswas S.K., Peixoto E.B., Souza D.S., and de Faria J.B. Hypertension increases pro-oxidant generation and decreases antioxidant defense in the kidney in early diabetes. Am. J. Nephrol. 28 (2008) 133-142
3. Bohlender J.M., Franke S., Stein G., and Wolf G. Advanced glycation end products and the kidney. Am. J. Physiol. Renal Physiol. 289 (2005) F645-659
4. Bouckenooghe T., Remacle C., and Reusens B. Is taurine a functional nutrient?. Curr. Opin. Clin. Nutr. Metab. Care 9 (2006) 728-733
5. Cameron N.E., Gibson T.M., Nangle M.R., and Cotter M.A. Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes. Ann. N. Y. Acad. Sci. 1043 (2005) 784-792
6. Casey R.G., Gang C., Joyce M., and Bouchier-Hayes D.J. Taurine attenuates acute hyperglycaemia-induced endothelial cell apoptosis, leucocyte-endothelial cell interactions and cardiac dysfunction. J. Vasc. Res. 44 (2007) 31-39
7. Coughlan M.T., Mibus A.L., and Forbes J.M. Oxidative stress and advanced glycation in diabetic nephropathy. Ann. N. Y. Acad. Sci. 1126 (2008) 190-193
8. Davì G., Falco A., and Patrono C. Lipid peroxidation in diabetes mellitus. Antioxid. Redox. Signal 7 (2005) 256-268
9. Emerson D.K., McCormick M.L., Schmidt J.A., and Knudson C.M. Taurine monochloramine activates a cell death pathway involving Bax and caspase-9. J. Biol. Chem. 280 (2005) 3233-3241
10. Forbes J.M., Fukami K., and Cooper M.E. Diabetic nephropathy: where hemodynamics meets metabolism. Exp. Clin. Endocrinol. Diabetes 115 (2007) 69-84
11. Franconi F., Loizzo A., Ghirlanda G., and Seghieri G. Taurine supplementation and diabetes mellitus. Curr. Opin. Clin. Nutr. Metab. Care 9 (2006) 32-36
12. Fukami K., Yamagishi S., Ueda S., and Okuda S. Novel therapeutic targets for diabetic nephropathy. Endocr. Metab. Immune Disord. Drug Targets 7 (2007) 83-92
13. Ha H., and Lee H.B. Reactive oxygen species amplify glucose signalling in renal cells cultured under high glucose and in diabetic kidney. Nephrology (Carlton) 10 (2005) S7-S10
14. Huang J.S., Chuang L.Y., Guh J.Y., Huang Y.J., and Hsu M.S. Antioxidants attenuate high glucose-induced hypertrophic growth in renal tubular epithelial cells. Am. J. Physiol. Renal Physiol. 293 (2007) F1072-F1082
15. Kim J.W., and Kim C. Inhibition of LPS-induced NO production by taurine chloramine in macrophages is mediated though Ras-ERK-NF-kappaB. Biochem. Pharmacol. 70 (2005) 1352-1360
16. Kim S.J., Gupta R.C., and Lee H.W. Taurine-diabetes interaction: from involvement to protection. Curr. Diabetes Rev. 3 (2007) 165-175
17. Lang F., Ritter M., Gamper N., Huber S., Fillon S., Tanneur V., Lepple-Wienhues A., Szabo I., and Gulbins E. Cell volume in the regulation of cell proliferation and apoptotic cell death. Cell Physiol. Biochem. 10 (2000) 417-428
18. Midwinter R.G., Peskin A.V., Vissers M.C., and Winterbourn C.C. Extracellular oxidation by taurine chloramine activates ERK via the epidermal growth factor receptor. J. Biol. Chem. 279 (2004) 32205-32211
19. Miyazaki T., Karube M., Matsuzaki Y., Ikegami T., Doy M., Tanaka N., and Bouscarel B. Taurine inhibits oxidative damage and prevents fibrosis in carbon tetrachloride-induced hepatic fibrosis. J. Hepatol. 43 (2005) 117-125
20. Pappa A., Franco R., Schoneveld O., Galanis A., Sandaltzopoulos R., and Panayiotidis M.I. Sulfur-containing compounds in protecting against oxidant-mediated lung diseases. Curr. Med. Chem. 14 (2007) 2590-2596
21. Rosado J.O., Salvador M., and Bonatto D. Importance of the trans-sulfuration pathway in cancer prevention and promotion. Mol. Cell Biochem. 301 (2007) 1-12
22. Sato T., Iwaki M., Shimogaito N., Wu X., Yamagishi S., and Takeuchi M. TAGE (toxic AGEs) theory in diabetic complications. Curr. Mol. Med. 6 (2006) 351-358
23. Satriano J. Kidney growth, hypertrophy and the unifying mechanism of diabetic complications. Amino Acids 33 (2007) 331-339
24. Schuller-Levis G.B., and Park E. Taurine and its chloramine: modulators of immunity. Neurochem. Res. 29 (2004) 117-126
25. Schutta M.H. Diabetes and hypertension: epidemiology of the relationship and pathophysiology of factors associated with these comorbid conditions. J. Cardiometab. Syndr. 2 (2007) 124-130
26. Tan A.L., Forbes J.M., and Cooper M.E. AGE, RAGE, and ROS in diabetic nephropathy. Semin. Nephrol. 27 (2007) 130-143
27. Trachtman H., Futterweit S., Prenner J., and Hanon S. Antioxidants reverse the antiproliferative effect of high glucose and advanced glycosylation end products in cultured rat mesangial cells. Biochem. Biophys. Res. Commun. 199 (1994) 346-352
28. Wilcox C.S. Oxidative stress and nitric oxide deficiency in the kidney: a critical link to hypertension. Am. J. Physiol. Regul. Integr. Comp. Physiol. 289 (2005) R913-R935
29. Williams M.E. New potential agents in treating diabetic kidney disease: the fourth act. Drugs 66 (2006) 2287-2298
30. Wu Q.D., Wang J.H., Fennessy F., Redmond H.P., and Bouchier-Hayes D. Taurine prevents high-glucose-induced human vascular endothelial cell apoptosis. Am. J. Physiol. 277 (1999) 1229-1238
31. Yamagishi S., Fukami K., Ueda S., and Okuda S. Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Curr. Drug Targets 8 (2007) 952-959
32. Yoshimura H., Nariai Y., Terashima M., Mitani T., and Tanigawa Y. Taurine suppresses platelet-derived growth factor (PDGF) BB-induced PDGF-beta receptor phosphorylation by protein tyrosine phosphatase-mediated dephosphorylation in vascular smooth muscle cells. Biochim. Biophys. Acta 1745 (2005) 350-360
33. Zhao W., Chen S.S., Chen Y., Ahokas R.A., and Sun Y. Kidney fibrosis in hypertensive rats: role of oxidative stress. Am. J. Nephrol. 28 (2008) 548-554